Literature DB >> 17487727

Skin lesions in chronic lymphocytic leukemia.

Ewa Robak1, Tadeusz Robak.   

Abstract

Cutaneous lesions occur in up to 25% of patients with chronic lymphocytic leukemia (CLL). These can be caused by either cutaneous seeding by leukemic cells (leukemia cutis, LC) and other malignant diseases or nonmalignant disorders. Skin infiltration with B-lymphocyte CLL manifests as solitary, grouped, or generalized papules, plaques, nodules, or large tumors. Prognosis in CLL patients with LC is rather good and many authors claim that it does not significantly affect patients' survival. However, prognosis is poor in patients in whom LC shows blastic transformation (Richter's syndrome) and when leukemic infiltrations in the skin appear after the diagnosis of CLL. Secondary cutaneous malignancies are also frequent complications in patients with CLL. A higher risk was seen in skin cancer, for which eightfold higher occurrence has been stated. There are some suggestions that alkylating agents and purine analogs may be associated with an increased incidence of secondary malignancies in CLL. Nonspecific, secondary cutaneous lesions are frequently observed in CLL patients. The most common secondary cutaneous changes seen in CLL are those of infectious or hemorrhagic origin. Other secondary lesions present as vasculitis, purpura, generalized pruritus, exfoliative erythroderma, and paraneoplastic pemphigus. An exaggerated reaction to an insect bite and insect bite-like reactions have been also observed.

Entities:  

Mesh:

Year:  2007        PMID: 17487727     DOI: 10.1080/10428190601137336

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  31 in total

Review 1.  The cutaneous manifestations of haematological malignancy.

Authors:  Abigail Fogo; Anthony du Vivier
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

2.  Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia.

Authors:  Abhenil Mittal; Ajay Gogia; Saumyaranjan Mallick; Ritu Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-06       Impact factor: 0.900

Review 3.  Chronic pruritus: a paraneoplastic sign.

Authors:  Gil Yosipovitch
Journal:  Dermatol Ther       Date:  2010 Nov-Dec       Impact factor: 2.851

4.  Diffuse painful plaques in the setting of chronic lymphocytic leukemia.

Authors:  Joseph Tadros; Cody Chastain; Eric Tkaczyk
Journal:  Cutis       Date:  2020-08

5.  Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Authors:  Paul J Hampel; Kari G Chaffee; Rebecca L King; Douglas Simonetto; Melissa C Larson; Sara Achenbach; Timothy G Call; Wei Ding; Saad S Kenderian; Jose F Leis; Asher A Chanan-Khan; Deborah A Bowen; Michael J Conte; Susan M Schwager; Curtis A Hanson; Susan L Slager; Neil E Kay; Tait D Shanafelt; Sameer A Parikh
Journal:  Am J Hematol       Date:  2017-10-19       Impact factor: 10.047

6.  Leukaemia cutis after starting bendamustine: cause or coincidence?

Authors:  Sagger Mawri; Shahzaib Nabi; Bassel Jallad; Joseph Won
Journal:  BMJ Case Rep       Date:  2015-09-21

Review 7.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 8.  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.

Authors:  Clive S Zent; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2011-06-08

9.  Successful pregnancy in the context of previously undiagnosed chronic lymphocytic leukaemia: A case report and literature review.

Authors:  Farshad Tahmasebi; Khawar Hussain; Georgina Smart; Manish Gupta; Upal Hossain
Journal:  Obstet Med       Date:  2017-05-10

10.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.